Virtual reality training for people with opioid use disorder
Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder: A Phase 2 Randomized Controlled Trial
This study tests if a virtual reality program can help people with opioid use disorder reduce their cravings and opioid use while they receive their usual treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 128 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | BehaVR LLC Industry-sponsored |
| Locations | 1 site (Salt Lake City, Utah) |
| Trial ID | NCT06021431 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of a virtual reality intervention called Mindfulness-Oriented Recovery Enhancement in Virtual Reality (MORE-VR) for individuals diagnosed with opioid use disorder who are already receiving medication. Participants will be randomly assigned to either receive MORE-VR alongside their usual treatment or continue with treatment as usual. The study aims to measure the impact of MORE-VR on the number of days participants use opioids, as well as their drug cravings and mood, at the end of treatment and three months later.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have a current diagnosis of opioid use disorder and are prescribed medication for their condition.
Not a fit: Patients who have previously completed a standardized mindfulness intervention or those with conditions contraindicated for virtual reality use may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce opioid use and improve recovery outcomes for patients with opioid use disorder.
How similar studies have performed: While the use of virtual reality in therapeutic settings is emerging, this specific approach has not been widely tested, making it a novel intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * current DSM-5 OUD diagnosis * prescribed medications for opioid use disorder (e.g., buprenorphine, methadone) Exclusion Criteria: * completion of a standardized mindfulness intervention (e.g., MORE, MBRP, MBSR) * active psychosis or suicidality * reports, or is noted by clinical or study staff as showing cognitive impairment * condition which might be contraindicated for VR use including seizure disorder, vertigo, severe motion sickness, recent concussion
Where this trial is running
Salt Lake City, Utah
- University of Utah — Salt Lake City, Utah, United States (Recruiting)
Study contacts
- Principal investigator: Risa Weisberg, PhD — BehaVR LLC
- Study coordinator: Risa Weisberg, PhD
- Email: risaweisberg@behavr.com
- Phone: 502-777-1593
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.